De novo design of modular and tunable protein biosensors
Alfredo Quijano-Rubio,
Hsien-Wei Yeh,
Jooyoung Park,
Hansol Lee,
Robert A. Langan,
Scott E. Boyken,
Marc J. Lajoie,
Longxing Cao,
Cameron M. Chow,
Marcos C. Miranda,
Jimin Wi,
Hyo Jeong Hong,
Lance Stewart,
Byung-Ha Oh () and
David Baker ()
Additional contact information
Alfredo Quijano-Rubio: University of Washington
Hsien-Wei Yeh: University of Washington
Jooyoung Park: University of Washington
Hansol Lee: Korea Advanced Institute of Science and Technology
Robert A. Langan: University of Washington
Scott E. Boyken: University of Washington
Marc J. Lajoie: University of Washington
Longxing Cao: University of Washington
Cameron M. Chow: University of Washington
Marcos C. Miranda: University of Washington
Jimin Wi: Kangwon National University
Hyo Jeong Hong: Kangwon National University
Lance Stewart: University of Washington
Byung-Ha Oh: University of Washington
David Baker: University of Washington
Nature, 2021, vol. 591, issue 7850, 482-487
Abstract:
Abstract Naturally occurring protein switches have been repurposed for the development of biosensors and reporters for cellular and clinical applications1. However, the number of such switches is limited, and reengineering them is challenging. Here we show that a general class of protein-based biosensors can be created by inverting the flow of information through de novo designed protein switches in which the binding of a peptide key triggers biological outputs of interest2. The designed sensors are modular molecular devices with a closed dark state and an open luminescent state; analyte binding drives the switch from the closed to the open state. Because the sensor is based on the thermodynamic coupling of analyte binding to sensor activation, only one target binding domain is required, which simplifies sensor design and allows direct readout in solution. We create biosensors that can sensitively detect the anti-apoptosis protein BCL-2, the IgG1 Fc domain, the HER2 receptor, and Botulinum neurotoxin B, as well as biosensors for cardiac troponin I and an anti-hepatitis B virus antibody with the high sensitivity required to detect these molecules clinically. Given the need for diagnostic tools to track the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)3, we used the approach to design sensors for the SARS-CoV-2 spike protein and antibodies against the membrane and nucleocapsid proteins. The former, which incorporates a de novo designed spike receptor binding domain (RBD) binder4, has a limit of detection of 15 pM and a luminescence signal 50-fold higher than the background level. The modularity and sensitivity of the platform should enable the rapid construction of sensors for a wide range of analytes, and highlights the power of de novo protein design to create multi-state protein systems with new and useful functions.
Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (7)
Downloads: (external link)
https://www.nature.com/articles/s41586-021-03258-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:591:y:2021:i:7850:d:10.1038_s41586-021-03258-z
Ordering information: This journal article can be ordered from
https://www.nature.com/
DOI: 10.1038/s41586-021-03258-z
Access Statistics for this article
Nature is currently edited by Magdalena Skipper
More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().